Aurobindo Pharma Limited has informed the Exchange about Transcript
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma reported highest-ever annual revenues of ₹33,653 crore and EBITDA of ₹6,856 crore (20.4% margin) for FY26. Q4 revenues were ₹8,853 crore with EBITDA of ₹1,801 crore (20.3% margin), delivering 2% YoY net profit growth to ₹921 crore despite negligible Revlimid sales. Ex-gRevlimid, full-year revenue grew 9.5% and Q4 grew 15.3%. Europe formulations hit the €1 billion annual milestone with 30% YoY growth in Q4. Management guided for FY27 EBITDA margins to sustain and improve above 21%, backed by multiple growth levers including the Lannett acquisition (expected early Q2 FY27), US business targeting $2 billion milestone in 1-2 years, and steady ramp-up of Pen-G/6-APA backward integration now contributing positively to margins. Biosimilar business is in early launch phase targeting 7-8 products in Europe and growth markets by 2030, with 2-3 US products, expecting gross margins of 65-75%. CDMO revenues expected to begin from 2031 for Unit-2 (Unit-1 from 2028).
Strong full-year performance with margin guidance of above 21% for FY27 signals management confidence in profitability improvement. Near-term catalysts include Lannett acquisition closing, new product launches in US, and scale-up of Pen-G exports. The multi-year pipeline across biosimilars, CDMO and specialty injectables provides long-term growth visibility.